PeptideStack
5.2kquestions
20kanswers
220users

Does a GLP-1 receptor agonist adsorb measurably to the vial wall at 1 mg/mL?

Asked 15 Apr 2025Modified 12 months agoViewed 9.4k times
19

Numbers first: a GLP-1 receptor agonist · 1 mg/mL.

I can do the algebra. I am not confident about the conversion factors.

If there is a standard way to lay this out, I would rather learn that than invent one.

Can someone show the working rather than just the answer?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
content-assay
content-assay

Quantified content: how many milligrams of peptide are actually in the vial, measured against a calibrated reference standard. A separate test…

476 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
shareeditfollowflag
TW
askedtare_and_weigh12k1615 Apr 2025
Do you know the residual moisture? It predicts this better than any date does. – e_dziedzic 3 days ago
add a comment

2 Answers

Sorted by votes
16

1 mg/mL is 1000 µg/mL — roughly 100 times the concentration at which surface adsorption is measurable. Losses to glass and plastic matter in the low microgram-per-millilitre range, where a monolayer on the wall is a real fraction of what is in solution. At 1 mg/mL that same monolayer is a rounding error. If you see an apparent loss at this concentration, suspect the dilution step or the assay before you suspect the wall.

Answer first: the degradation pathways worth knowing are hydrolysis, deamidation, oxidation, aggregation and adsorption, and each has a different trigger and a different mitigation.

Adsorption onto glass and plastic is significant at low concentrations — micrograms per millilitre — and negligible at milligrams per millilitre. It is the usual explanation for an apparent loss in a dilute preparation.

Degradation pathway by condition

PathwayDominant whenDetected by
DeamidationSolution, neutral to alkaline pHRP-HPLC, +1 Da on MS
OxidationLight, trace metals, peroxidesRP-HPLC, +16 Da on MS
HydrolysisSolution, extremes of pHRP-HPLC, fragment masses
AggregationAgitation, interfaces, high concentrationSEC, visual haze; often invisible on RP-HPLC
Freeze-concentration damageFreeze-thaw of buffered solutionSEC, loss of recovered content

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

At dilute concentrations, suspect adsorption before you suspect chemistry.

edited 26 Jul 2025 by h_pergande — clarified the distinction between purity and content

shareimprove this answerflag
HP
answeredh_pergande71k1581 Jul 2025
7Adding for future readers: the domestic leg after delivery is the part you control. – t_oyelaran 3 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
12

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Swirl, never shake. Aggregation is a handling problem more than a time problem.

shareimprove this answerflag
LC
answeredlyoph_cake78k26720 Jun 2025
2Aliquoting before the first freeze is the advice I wish I had read two years ago. – kwn_analytical 7 months ago
Same experience here, different supplier. – s_bhattacharya 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.